Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs Sana Biotechnology Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.3, while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| GPTY | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $5.92 |
52-Week Low | $34.73 | $2.68 |
Market Cap | — | $987.94M |
Enterprise Value | — | $962.13M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $41.41, down 3.97% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.30 to $0.38. Support and resistance levels cluster tightly around $43-$46, indicating potential for near-term consolidation. Recent news highlights focus on its option-income strategy and comparisons to peers like ULTY.
The outlook balances high yield potential against market volatility risks. Investment appeal centers on AI/tech exposure coupled with income generation, but reliance on semiconductor momentum and option premiums introduces volatility. Key risks include NAV erosion from the covered call strategy and sector concentration, requiring careful risk assessment for income-focused investors.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
